A publicly traded company focused on oncology therapeutics is seeking therapeutic opportunities in the oncology space. The firm is looking to partner and collaborate as well as in-license, but is primarily seeking partnerships. The firm seeks assets that have at the very least cellular proof of concept, but prefers companies to have some animal data or are approaching pre-IND studies. The firm is also willing to partner with unique and differentiated drug discovery platform companies. The firm will partner globally, but primarily partners with US and Europe-based companies.

The firm is interested only in oncology and immuno-oncology assets in high unmet tumor indications including RCC and HCC. For modality, the firm is interested only in small molecule and biologics. The firm is willing to consider therapeutics targeting both solid and liquid tumors. The firm will also partner with drug discovery companies, such as those using AI-based technologies to identify new therapeutic biology, as well as platform companies.

The firm will only partner with companies that have a strong IP position and a clear differentiating discovery and development strategy. The firm looks for startups with unique “First-in-Class” therapeutics and platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in USA and Asia with limited partners including institutional investors from US and China, typically invests $5-10M in businesses from Series A to pre-IPO and public traded companies. The firm is open to leading or following a syndicated round. The firm is now seeking opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observer ship on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital and growth equity firm provides $15-$40 million of equity capital per company over the life of the investment. With offices in USA and Europe, the firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is generally open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and the firm most always looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is the venture arm of the world’s leading provider of products and services for people with chronic kidney failure. The Corporate VC has offices in USA, Germany, and Israel, and is actively seeking early-stage investment opportunities that align with the parent company’s core businesses. Typical size of investment is around $5M, and the firm focuses on Series A to B rounds. The fund is open to global opportunities.

The Corporate VC is interested in products and technologies across therapeutics, medical devices, diagnostics, and digital health that target the following therapeutic sectors: chronic kidney disease and dialysis, intensive care medicine, cardiovascular diseases, autoimmune diseases, diabetes, and other kidney-related diseases. In terms of medical devices, the firm is open to 510k and PMA regulatory pathways.

The Corporate VC is open to working with all types of management teams. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The firm is a publicly NASDAQ-traded diagnostics company with operations in China and the United States. The company specializes in pre-cancer and cancer screening based on biophysical properties. The firm is looking to partner or acquire a majority share in early stage companies in the diagnostics space. While the firm is looking to be the majority stakeholder in these companies, the firm is most interested in continuing a partnership/joint venture with these startups, as opposed to a full acquisition. The firm is willing to partner globally.

The firm is interested in diagnostics companies only. Within diagnostics, the firm is interested in two types of partnerships. First, the firm is seeking oncology diagnostics that use genetic or biomarker identification of specific cancer types that can be paired with their technology, meshing the specific genetic/biomarker for these cancers with the biophysical anomalies they detect. Additionally, the firm is also looking to partner with companies in the oncology space that are seeking to expand to China and can take advantage of the firm’s existing infrastructure. For these partnerships, the firm is interested in all forms of diagnostics in all indications.

The firm is looking to acquire at least a 51% stake in the companies with which they are partnering, but is open to any structures that are advantageous for all parties. As a partner, the firm has facilities in place for any additional research or clinical tests needed to help companies reach commercialization in the United States, as well as the ability to help with distribution, especially in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A Japanese Pharmaceutical company, with headquarters in Tokyo and offices in Japan and the US focuses on developing and marketing products in the pharmaceutical and nutraceutical businesses. Currently, the Pharma is actively seeking novel and innovative therapeutic opportunities for in-licensing in CNS and nephrology. In addition, the Pharma manages an early-stage investment fund (currently $30M) that actively invests in global early-stage opportunities that fit the firm’s areas of interest.

The Pharma is interested in innovative therapeutics that address areas of significant unmet need in CNS and renal diseases. The firm is a global leader in CNS, both neurology and psychiatry, opportunistic to all types of indications, both symptomatic and disease-modifying. In nephrology, the firm is particularly interested in novel mechanism addressing both acute and chronic kidney diseases of tubular and glomerular origin, as well as associated inflammatory and fibrotic mechanisms. The firm will consider both clinical and pre-clinical compounds with compelling biological valid proof-of-concept.

The Pharma has no specific management team requirements and will work with all types of companies with an innovative product or pipeline. The firm aims to obtain global commercial rights as a preferential end-goal.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm founded in 2015 and based in Silicon Valley makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare , including AI in healthcare and medical devices. The firm manages 3 funds right now with over $200M AUM. The firm typically invests $1M-$2M initial check per company, and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies.

The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage.

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.